Targets › CEA
8 programs from 6 companies in 12 trials: 8 Phase 1, 3 Phase 2, 1 Phase 3; Oncology; next expected readout Nov 2026.
Cell surface glycoprotein that plays a role in cell adhesion, intracellular signaling and tumor progression. Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM6. (UniProt, P06731)
Open in Phaseline: the race on CEA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| OSE Immunotherapeutics | OSE2101 peptidic cancer vaccine with nine HLA-A2-restricted epitopes targeting tumor-associated an | TP53, ERBB2, CEA, MAGEA2, MAGEA3 | Phase 3 | Patients With Non-Small Cell Lung Cancer; Solid Advanced Tumor | Dec 2027 |
| National Cancer Institute (NCI) | Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5 Therapeutic cancer vaccine expressing CEA, MUC1, and Brachyury tumor-associated antigens | CEA, MUC1, TBXT | Phase 2 | Colorectal Carcinoma | Jul 2027 |
| Fondazione Ricerca Traslazionale | Tedopi Cancer vaccine inducing cytotoxic T-lymphocytes against tumor-associated antigens (CEA, p5 | CEA, TP53, ERBB2, MAGE2, MAGE3 | Phase 2 | Metastatic Non Small Cell Lung Cancer | Sep 2027 |
| National Cancer Institute (NCI) | Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform Adenoviral-based cancer vaccine targeting CEA, Brachyury and MUC1 | CEA, BRACHYURY, MUC1, KLK3, TBXT | Phase 2 | Adenocarcinoma; Metastatic Colorectal Cancer | Oct 2027 |
| Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | CEA protein antigen plus BCG Vaccine Mix CEA antigen with trained immunity via BCG; APCs process CEA antigen into peptide fragments | CEA | Phase 1 | Rectal Cancer | Nov 2026 |
| Beijing Biotech | EB-DUO-CAR-NK-CEA/GCC Dual-target CAR-NK cell therapy targeting CEA and GUCY2C (or CEA and HER2, or GUCY2C and H | CEACAM5, GUCY2C, ERBB2, CEA, HER2, IL15 | Phase 1 | Colorectal Cancer; Colorectal Cancer Metastatic | Mar 2027 |
| National Cancer Institute (NCI) | Falimarev (Fowlpox-CEA-MUC-1-TRICOM) Recombinant fowlpox virus expressing CEA and MUC-1 tumor-associated antigens with TRICOM c | CEA, MUC1 | Phase 1 | Locally Advanced Pancreatic Adenocarcinoma | Apr 2027 |
| City of Hope Medical Center | M5A-IL2 immunocytokine CEA-targeting immunocytokine; fuses M5A anti-CEA antibody to IL-2 cytokine to activate imm | CEA | Phase 1 | Breast Carcinoma | Mar 2029 |
Locally Advanced Pancreatic Adenocarcinoma (2) Adenocarcinoma (1) Metastatic Colorectal Cancer (1) Patients With Non-Small Cell Lung Cancer (1) Solid Advanced Tumor (1) Colorectal Cancer (1) Colorectal Cancer Metastatic (1) Rectal Cancer (1) Metastatic Non Small Cell Lung Cancer (1) Colorectal Carcinoma (1) Breast Carcinoma (1)
mixed (4), small molecule (2), protein or peptide (1), other (1)
National Cancer Institute (NCI) (3) OSE Immunotherapeutics (1) Beijing Biotech (1) Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair (1) Fondazione Ricerca Traslazionale (1) City of Hope Medical Center (1)
MUC1 (3) ERBB2 (3) TBXT (2) TP53 (2) BRACHYURY (1) KLK3 (1) MAGEA2 (1) MAGEA3 (1) CEACAM5 (1) GUCY2C (1) HER2 (1) IL15 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.